BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27794410)

  • 21. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.
    Verma V; Moreno AC; Haque W; Fang P; Lin SH
    J Natl Compr Canc Netw; 2018 May; 16(5):508-516. PubMed ID: 29752325
    [No Abstract]   [Full Text] [Related]  

  • 22. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
    Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M
    Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer.
    Scagliotti GV; Douillard JY
    Lung Cancer; 2004 Dec; 46 Suppl 2():S13-21. PubMed ID: 15698527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Naito Y; Kubota K; Nihei K; Fujii T; Yoh K; Niho S; Goto K; Ohmatsu H; Saijo N; Nishiwaki Y
    J Thorac Oncol; 2008 Jun; 3(6):617-22. PubMed ID: 18520801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
    Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
    Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
    Zheng Q; Min S; Zhou Y
    BMC Cancer; 2022 Jun; 22(1):674. PubMed ID: 35725420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer.
    Wu HG; Bang YJ; Choi EK; Ahn YC; Kim YW; Lim TH; Suh C; Park K; Park CI
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):75-80. PubMed ID: 11777624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.
    Michael M; Wirth A; Ball DL; MacManus M; Rischin D; Mileshkin L; Solomon B; McKendrick J; Milner AD
    Br J Cancer; 2005 Sep; 93(6):652-61. PubMed ID: 16222311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma.
    Robnett TJ; Machtay M; Stevenson JP; Algazy KM; Hahn SM
    J Clin Oncol; 2001 Mar; 19(5):1344-9. PubMed ID: 11230477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
    Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
    Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T
    J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer.
    Bobbili P; Ryan K; DerSarkissian M; Dua A; Yee C; Duh MS; Gomez JE
    PLoS One; 2020; 15(3):e0230444. PubMed ID: 32187231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.
    Kawaguchi T; Takada M; Ando M; Okishio K; Atagi S; Fujita Y; Tomizawa Y; Hayashihara K; Okano Y; Takahashi F; Saito R; Matsumura A; Tamura A
    Eur J Cancer; 2012 Mar; 48(5):672-7. PubMed ID: 22172569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.